| Phase 3, Randomized, Open-Label Trial of MK-5684 Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With a next-generation hormonal agent (NHA) and taxane-based chemotherapy. (MK-5684-003) |
This trial is testing MK-5864 in men with metastatic castration-resistant prostate cancer (mCRPC). This trial will compare MK-5684 to abiraterone acetate or enzalutamide. This study aims to compare the safety and effectiveness of MK-5864 with standard treatments. In addition, we will determine whether the life expectancy of participants treated with MK-5684 is longer than that of participants treated with abiraterone acetate or enzalutamide.
Stade de la Maladie: Métastatique
Organe: Prostate
Maladie: mCRPC
